WO2006097828A2 - Assay for myelosuppression - Google Patents
Assay for myelosuppression Download PDFInfo
- Publication number
- WO2006097828A2 WO2006097828A2 PCT/IB2006/000584 IB2006000584W WO2006097828A2 WO 2006097828 A2 WO2006097828 A2 WO 2006097828A2 IB 2006000584 W IB2006000584 W IB 2006000584W WO 2006097828 A2 WO2006097828 A2 WO 2006097828A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- compound
- oxazolidinone
- assay
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
Definitions
- the invention provides a method of identifying the myelosuppressive liability of antibacterial oxazolidinone compounds.
- the oxazolidinones are a new structural class of antibiotics, with activity against several Gram-positive organisms, including several resistant strains.
- the oxazolidinones inhibit bacterial protein synthesis.
- Linezolid is a synthetic antibacterial agent of a new class of antibiotics, the oxazolidinones.
- the in vitro spectrum of activity of linezolid includes aerobic Gram-positive bacteria, certain Gram-negative bacteria and anaerobic bacteria.
- Clinically, linezolid therapy results in minimal side effects for most patients.
- reversible myelosuppression characterized by anemia, leukopenia, pancytopenia, and thrombocytopenia, has been infrequently observed in patients treated with linezolid for at least 21 days. The mechanism of this effect is not known, but it has been suggested that the myelosuppression may result from linezolid inhibition of mitochondrial protein synthesis. .
- the invention provides a method of identifying the myelosuppressive liability of an antibacterial oxazolidinone compound comprising subjecting a test oxazolidinone compound to analysis in a mitochondrial protein synthesis (MPS) assay and in at least two cell proliferation assays performed with cultures of two different mammalian cells.
- the IC 50 of the oxazolidinone test compound in each of the three assays is determined; and compared to the IC 50 of a reference oxazolidinone in each assay.
- the test compound has less myelosuppressive liability than the reference oxazolidinone if the ICso in at least two of the assays is higher than the IC 5 O of the reference oxazolidinone.
- the reference oxazolidinone is linezolid.
- the mitochrondrial protein synthesis assay may be performed on mitochrondria isolated from the group consisting of mammalian tissues and mammalian cells.
- the mammalian tissue may be selected from heart and liver.
- the mammalian cells are selected from the group consisting of cultured cells and primary cells.
- the mammalian cells may be selected from the group consisting of CD34 + cells, K562 cells, CHO cells, HEK cells, and osteosarcoma derived cells.
- the cells are selected from the group consisting of platelets, neutrophils and red blood cells.
- the method of the present invention relates to identification of the myelosuppressive liability of antibacterial oxazolidinone compounds.
- myelosuppression is defined as a decrease in bone marrow activity resulting in lower numbers of red blood cells, white blood cells or platelets in circulation.
- myelosuppressive liability refers to the capability of a compound to cause myelosuppression. Peripheral blood measurements of red blood cells, hemoglobin, reticulocytes, white blood cells, white blood cell differential and platelets are used to assess myelosuppression in humans. In animal studies, a direct assessment of myelosuppression by measurement of the bone marrow contents can also be performed.
- the nucleated cell types commonly measured within the bone marrow include erythroid (red blood cell), myeloid (white blood cell) and lymphocyte (white blood cell) progenitor cells, as well as megakaryocytes (platelet producing cells). Decreases in the total number of nucleated cells (TNC) or changes in the ratio of myeloid to erythroid progenitors (M:E ratio) are typically used to assess the degree of myelosuppression as well as the cell types which are affected.
- the method of the present invention comprises testing oxazolidinone compounds in at least three assays and comparing the inhibition of protein synthesis in the mitochondrial protein synthesis (MPS) assay (the ICs 0 ) with that of a reference oxazolidinone, and comparing the IC 50 of inhibition of cell growth in at least two types of mammalian cells with that of a reference oxazolidinone.
- the assay of the IC50 of the reference oxazolidinone can be done at the same time as the assay of the test compound or the results of the test oxazolidinone may be compared to historical data obtained for a reference oxazolidinone.
- the reference oxazolidinone may be selected from the group consisting of linezolid, eperezolid and any other antibacterial oxazolidinone.
- IC 50 refers to the concentration of compound that results in a 50% inhibition of a measured response.
- Response refers to, for example, growth of cells or protein synthesis activity.
- Mitochondrial protein synthesis may also be measured by measuring the synthesis of individual mitochondrial proteins.
- Mitochondria useful in the MPS assay may be isolated from any mammalian source.
- mitochondria may be isolated from mammalian tissues, such as heart and liver; from cultured mammalian cells, including primary cells or established cell lines; and from blood cells such as platelets, neutrophils or red blood cells. The methods for the measurement of cell proliferation are well known.
- Mammalian cell lines may be selected from the group consisting of CD34 + cells, K562 cells, CHO cells, HEK cells, and osteosarcoma derived cells may be utilized and the effect of the test oxazolidinone on cell proliferation determined.
- the IC 50 of a test compound is determined by incubation the cells for a period of time of at least 24 hours in the presence and absence of the test compound or the reference oxazolidinone and measuring the viable cell number at the end of the incubation period.
- Cell numbers may be directly counted using a hemocytometer or a Coulter counter instrument.
- Other methods of assessing cell proliferation include measuring the uptake of radioactively labeled compound such as [ 3 H] thymidine uptake measurements, or incorporation of BrdU )5-bromo-2'-deoxyuridine.
- MTT 3-[4,5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
- MTT is a yellow salt and is cleaved to yield purple formazan crystals by metabolically active, viable cells (Roche Applied Sciences, Penzberg, Germany; Catalog # 1-465-007).
- the presence of the product (formazan) is measured at 550 ran and background absorbance was measured at 650 nm.
- a CellTiter-Glo Luminescent Cell Viability Assay (Catalog # TB288, Promega Corporation, Madison, WI) measures the ATP present in viable cells, which is a direct correlation to the number of viable cells present in a culture.
- luciferin in the presence of ATP and the enzyme lucif erase, forms a luminescent product, oxyluciferin, which is measured in a luminometer.
- the concentration of compound versus the cell number quantitation is analyzed to yield an IC 50 value.
- An IC 50 value is the concentration of compound that inhibits cell growth by 50%. Data is analyzed using GraphPad Prism 4, and fitted to a sigmoidal dose-response (variable slope) curve to generate IC 5O values.
- DME Dulbeccos's modified Eagle
- GBCO high glucose medium
- fetal bovine serum fetal bovine serum
- 1 mM sodium pyruvate 1 mM sodium pyruvate
- 50 ⁇ g/ml uridine as described by King and Attardi ((1989) Science 246: 500-503).
- the cells were obtained from G. Attardi and A. Chomyn (California Institute of Technology).
- Human embryonic kidney (HEK) cells were cultured in DME High Glucose medium supplemented with 10% fetal bovine serum, 4 mM L-glutamine and 1 mM sodium pyruvate.
- Human erythroleukemia K562 cells were obtained from ATCC and grown in RPMI 1640 medium (GIBCO, Grand Island, NY) containing 25 mM Hepes buffer, 1.5 mM Glutamax and 10% fetal bovine serum.
- oxazolidinone compounds were prepared in 100% dimethyl sulfoxide (DMSO), and the final DMSO concentration in the assay was 0.5%.
- quantitation of proliferation was carried out either by cell counting using a Coulter counter, by using the dye MTT (Roche Cell Proliferation Kit)( Roche Applied Sciences, Germany) or by using a CellTiter-Glo Luminescent Cell Viability Assay (Catalog # TB288, Promega Corporation, Madison, WI).
- absorbance was measured at 550 and 650 nm (background) on a SpectraMax spectrophotometer. The difference between the absorbances was calculated and data was analyzed as described above using GraphPad Prism 4, and fitted to a sigmoidal dose-response (variable slope) curve to yield an IC50 value for the oxazolidinone compound being tested.
- CD34+ cells Fresh human CD34+ cells (IM-IOIb) were purchased from Cambrex Bio Science Walkersville, Inc (Walkersville, MD). Each batch of CD34+ cells was derived from the bone marrow of a healthy donor and was > 95% pure. CD34+ cells were resuspended in HPGM (Hematopoietic progenitor growth medium) (Cambrex) medium containing 2 mM glutamine, 200 ⁇ g/ml transferrin, 50ng/ml Stem Cell Factor (SCF, R & D Systems, Inc., Minneapolis, MN) and 6 units/ ml erythropoietin (EPO, R & D Systems) at a concentration of 20,000 cells/ml.
- HPGM Hematopoietic progenitor growth medium
- SCF Stem Cell Factor
- EPO erythropoietin
- diluted cells 2000 cells were plated in 96 well flat bottom plates and 100 ⁇ l of a test oxazolidinone compound was added to each well.
- Compound stocks were prepared in 100% DMSO, and the final DMSO concentration in the assay was 0.1%. Positive control wells contained cells in the absence of any compound, and negative control wells did not have compound, SCF or EPO added. Both positive and negative controls contained 0.1% DMSO. All dilutions of each compound were assayed in duplicate in a given assay. Linezolid (diluted in the same way as other test compounds) was run in every assay as a standard.
- the plates were placed in a humidified chamber and incubated for 9 to 10 days in 5% CO 2 at 37 0 C. At the end of the incubation lOO ⁇ l of CellTiter-Glo Luminescent Cell Viability Assay reagent (Promega Corporation, Madison, WI) was added to each well and mixed. An aliquot (100 ⁇ l) from each well was removed and transferred to an opaque 96-well plate, and luminescence was read in a Wallac Victor2 luminometer. Data was analyzed as described above using GraphPad Prism 4 (GraphPad Software, Inc.) using the equation for sigmoidal dose response with variable slope.
- FACS analysis demonstrated that the cells were not undergoing cell cycle arrest.
- the compound slowed the growth by increasing the doubling time of the treated cultures.
- the time course data was used to plot the concentration- dependency curve of growth inhibition.
- the IC 50 for growth inhibition by eperezolid in K562 cells for a 5-day exposure was 12 ⁇ M.
- the inhibition of proliferation by eperezolid was reversed upon withdrawal of compound from the growth media.
- Cells were grown in either 15 ⁇ M or 30 ⁇ M compound for 72 hours followed by removal of the media, washing, and refeeding the cells with media containing either vehicle, 15 ⁇ M or 30 ⁇ M eperezolid. Cells then were cultured for an additional 5 days.
- Eperezolid inhibited proliferation of human HEK cells and Chinese hamster ovary (CHO) cells, as well as mouse BB88 cells.
- the IC 50 value for eperezolid varied somewhat between the various cell types, and was 63 ⁇ M, and 20 ⁇ M, for CHO and HEK cells, respectively. In all cases, a progressive slowing of growth due to an increase in cell doubling time was observed.
- Rat heart The procedure for mitochondria preparation and the protein synthesis assay was adapted from that described by McKee et al. Briefly, male Sprague-Dawley rats (-250 grams) were anesthetized by inhalation of isoflurane, injected with heparin IV, and the heart was removed and rinsed in ice-cold MSE buffer (220 mM mannitol, 70 mM sucrose, 50 mM HEPES, 2mM EGTA, pH 7.2) until free of blood. Hearts were minced in MSE buffer containing 10 mg/ml Nagarse (Sigma), washed once, and homogenized in MSE-Nagarse buffer using a Brinkman polytron.
- MSE buffer 220 mM mannitol, 70 mM sucrose, 50 mM HEPES, 2mM EGTA, pH 7.2
- Protease inhibitor (Complete, Boehringer) then was added to the homogenate.
- the homogenate was centrifuged at 900 x g for 3 min and the resulting supernatant was centrifuged at 10,000 x g for 10 min.
- the pellet was resuspended in 1.0 ml of ice-cold MSE buffer at a ratio of 20 ml/gram ventricular tissue and centrifuged at a speed of 900 x g for 3 min at 4°C.
- the resulting supernatant was centrifuged at 10,000 x g for 10 min at 4°C.
- Pellets were resuspended in MSE buffer and protein was determined (Bio-Rad).
- K562 cells were incubated with compound or vehicle for 5 days and cells were collected, washed once with PBS, and resuspended in 1 ml of TKM buffer (10 mM Tris HCL pH 7.5, 1OmM KCL and 0.15 mM NaCl) and homogenized with a hand-held homogenizer (Ultra-Turrax, IKA Labotechnik) at setting 3 for 15 sec. An aliquot (300 ul) of TKM buffer containing IM sucrose was added and the samples were centrifuged at lOOOg for 5 min. The supernatant fraction was respun at 5000g for 20 min. The mitochondrial pellet was resuspended in TKM buffer containing 0.25 M sucrose in lOOul volume. Mitochondrial protein content was measured using the BCA protein assay kit (Pierce).
- Mitochondrial Protein Synthesis (MPS) Assay Mitochondrial protein synthesis was measured in 50 ⁇ l total volume containing 90 mM KCL, 4 mM MgSO 4 , 2.5 mM KH 2 PO 4 , 50 mM HEPES pH 7.2, 0.25 mM amino acids without methionine, 20 mM glutamate, 0.5 mM malate, 2 mM ADP, 1 mg/ml BSA (Sigma A3059), 0.1 mg/ml Cycloheximide (Sigma D-335715), 1 ⁇ M cold methionine,
- Mitochondrial proteins (10 ⁇ g) were electrophoresed on 10% Criterion gels (Bio-Rad ) and transferred to
- PVD membranes (Bio-Rad ). After blocking overnight at 4° C with 1% BSA and 1% dry milk in Tris-buffered saline (Bio-Rad) containing 0.1% Tween 20, the membranes were incubated with lug/ml cytochrome C oxidase subunit 1 (Cox-1) monoclonal antibody (Molecular Probes A-6403) for 3 hrs, followed by chemiluminescent detection (Amersham ECL plus) according to the manufacturer's instructions. Membranes were stripped by RE-blot Plus strong solution (Chemicon 2504) and incubated with lug/ml Tom-20 polyclonal antibody (Gift from Dr. B. Wattenberg, Univ. Louisville), followed by chemiluminescent detection. The Cox-1 bands and Tom-20 bands in the X-ray films were scanned by Personal Densitometer SL (Molecular Dynamics) and quantitated by Quantity One (Bio-Rad).
- the level of mitochondrial proteins in K562 cells was examined to determine whether oxazolidinones inhibited mitochondrial protein synthesis in intact cells.
- K562 cells were incubated with varying concentrations of eperezolid for 5 days under the same conditions as eperezolid. The cells were harvested and the mitochondria were isolated. This mitochondrial fraction was run on Western blots as described above and probed with a monoclonal antibody to subunit 1 of cytochrome oxidase, which is one of the 13 proteins encoded by the mitochondrial genome ( Figure 6).
- To normalize for mitochondrial protein loading after exposure to the Cox-1 antibody the blots were stripped and re-probed with an antibody to
- Tom 20 an outer mitochondrial membrane protein encoded by the nucleus.
- Tom 20 protein levels were relatively constant across the gel.
- Cox-1 protein expression decreased with increasing concentrations of eperezolid, and 25 uM eperezolid resulted in a greater than 90% decrease in Cox-1 levels.
- As a control cells also were treated with 100 uM chloramphenicol, a known mitochondrial protein synthesis inhibitor. Almost complete inhibition of Cox-1 levels was observed with this compound, which also inhibited the proliferation of the cells.
- the decreased level of mitochondrial protein was not specific for Cox-1, since 35 S-methionine labeling of mitochondria isolated from oxazolidinone-treated cells showed decreased incorporation of radioactivity into all 13 mitochondrial proteins.
- eperezolid resulted in a time and concentration-dependent decrease in 143B cell number.
- the IC 50 value was ⁇ 20 uM.
- growth of rho zero cells was not inhibited by treatment with any concentration of the two mitochondrial protein synthesis inhibitors, eperezolid or chloramphenicol.
- eperezolid As a control, to demonstrate that rho 0 cells are not resistant to all types of growth arrest, cells were treated with etoposide, a topoisomerase H inhibitor, or with cycloheximide. As expected both these compounds inhibited growth of rho 0 cells, as well as the 143B cells.
- Hematological parameters were evaluated on Day 14 prior to dosing for the day. Blood samples containing EDTA were evaluated for the following parameters using an automated hematology analyzer (e.g. Advia 120):
- red cell count platelet count hemoglobin mean platelet volume hematocrit white cell count mean corpuscular volume white cell differential mean corpuscular hemoglobin reticulocyte count mean corpuscular hemoglobin red cell distribution width concentration
- AU animals were euthanized using carbon dioxide inhalation.
- a single femur from each surviving animal was collected and the bone marrow contents were flushed from the bone and resuspended in fetal bovine serum.
- Cells were washed in PBS and a fraction of the sample was used to determine a total nucleated cell count using an automated hematology analyzer. The remaining sample was stained with either 2'7'-Dichlorofluorescin (DCF) to detect erythroid progenitors, myeloid progenitors, and megakaryocytes or with antibodies specific to lymphocyte progenitor cells. Samples were analyzed by a flow cytometer (e.g.
- Coulter EPICS XL Coulter EPICS XL
- erythroid progenitors myeloid progenitors, megakaryocytes and lymphocyte progenitors were determined by the operator using cell size and fluorescence as indicators of cell type.
- Statistical analyses were conducted for body weight and weight change, food consumption, hematology and bone marrow data. Treatment comparisons were performed on rank-transformed data using a dose-trend test sequentially applied at the two-tailed 1% and 5% significance levels within one-factor analysis of variance (ANOVA). Dunnett's test replaced the sequential trend test if the overall linear trend test was not significant at the 5% level and a quadratic trend is significant at the 1% level.
- ANOVA analysis of variance
- Compound A the ICs 0 S for the MPS, K562, and CD34 assays were 82, 55, and 21 ⁇ M, respectively, compared with IC 50 s of 20, 14, and 6.2 ⁇ M for linezolid (the reference oxazolidinone).
- Compound A was evaluated in rats in vivo for myelosuppression, at exposures comparable to those of linezolid which produced significant decreases in reticulocytes (97%) and RBCs, and an 8.4-fold increase in M:E ratio, Compound A produced less myelosuppression (slight decreases in reticulocytes (35%) and no changes in bone marrow cells or M:E ratio).
- Compound B With another antibacterial oxazolidinone, Compound B, the IC 5 os for the MPS, K562, and CD34 assays were 81, 248, and 67 ⁇ M, respectively, compared with IC 50 S of 19, 23, and 11 ⁇ M for linezolid (the reference oxazolidinone).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66299705P | 2005-03-18 | 2005-03-18 | |
US60/662,997 | 2005-03-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006097828A2 true WO2006097828A2 (en) | 2006-09-21 |
WO2006097828A3 WO2006097828A3 (en) | 2007-01-18 |
Family
ID=36992106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2006/000584 WO2006097828A2 (en) | 2005-03-18 | 2006-03-13 | Assay for myelosuppression |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006097828A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010047737A2 (en) | 2008-09-02 | 2010-04-29 | Micurx Pharmaceuticals, Inc. | Antimicrobial indoline compounds for treatment of bacterial infections |
CN104280473A (en) * | 2014-10-23 | 2015-01-14 | 江苏正大丰海制药有限公司 | Analysis method of 5-hydroxymethylfurfural in linezolid injection |
-
2006
- 2006-03-13 WO PCT/IB2006/000584 patent/WO2006097828A2/en not_active Application Discontinuation
Non-Patent Citations (4)
Title |
---|
"Drug-induced myelosuppresion requires early recognition, accurate diagnosis and supportive treatment" DRUGS AND THERAPY PERSPECTIVES 2004 NEW ZEALAND, vol. 20, no. 10, 2004, pages 23-26, XP009073151 ISSN: 1172-0360 * |
KUTER DAVID J ET AL: "Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid" PHARMACOTHERAPY, vol. 21, no. 8, August 2001 (2001-08), pages 1010-1013, XP009073150 ISSN: 0277-0008 * |
NAGIEC EVA E ET AL: "Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 49, no. 9, September 2005 (2005-09), pages 3896-3902, XP002400972 ISSN: 0066-4804 * |
SCIOTTI RICHARD J ET AL: "The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 16, 19 August 2002 (2002-08-19), pages 2121-2123, XP002401214 ISSN: 0960-894X * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010047737A2 (en) | 2008-09-02 | 2010-04-29 | Micurx Pharmaceuticals, Inc. | Antimicrobial indoline compounds for treatment of bacterial infections |
CN104280473A (en) * | 2014-10-23 | 2015-01-14 | 江苏正大丰海制药有限公司 | Analysis method of 5-hydroxymethylfurfural in linezolid injection |
Also Published As
Publication number | Publication date |
---|---|
WO2006097828A3 (en) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Condorelli et al. | Effects of myoinositol on sperm mitochondrial function in-vitro | |
US7700354B2 (en) | High throughput stem cell assay for identifying stem cells useful for transplantation | |
Kuliawat et al. | Potent humanin analog increases glucose-stimulated insulin secretion through enhanced metabolism in the β cell | |
US20060147947A1 (en) | AMPK pathway components | |
Mirandola et al. | Exogenous hydrogen sulfide induces functional inhibition and cell death of cytotoxic lymphocytes subsets | |
Malaiyandi et al. | Zn2+ inhibits mitochondrial movement in neurons by phosphatidylinositol 3-kinase activation | |
AU2002335610A1 (en) | High-throughput stem cell assay of hematopoietic stem and progenitor cell proliferation | |
Orlicka-Płocka et al. | Circumventing the Crabtree effect: forcing oxidative phosphorylation (OXPHOS) via galactose medium increases sensitivity of HepG2 cells to the purine derivative kinetin riboside | |
Maile et al. | An essential role for the association of CD47 to SHPS‐1 in skeletal remodeling | |
Deutsch et al. | pH homeostasis in human lymphocytes: modulation by ions and mitogen. | |
Çadirci et al. | The in vitro cytotoxic, genotoxic, and oxidative damage potentials of the oral artificialsweetener aspartame on cultured human blood cells | |
Amer et al. | Oxidative status of red blood cells, neutrophils, and platelets in paroxysmal nocturnal hemoglobinuria | |
Plachta et al. | Nitric oxide is involved in establishing the balance between cell cycle progression and cell death in the developing neural tube | |
Uzbekov | Analysis of the cell cycle and a method employing synchronized cells for study of protein expression at various stages of the cell cycle | |
WO2006097828A2 (en) | Assay for myelosuppression | |
Abdollahi et al. | L‐Arginine/Nitric Oxide Pathway and Interaction with Lead Acetate on Rat Submandibular Gland Function | |
Jane Rogers et al. | Competitive effect of magnesium on the calcium-dependent acrosome reaction in guinea pig spermatozoa | |
Titenko‐Holland et al. | Studies on the genotoxicity of molybdenum salts in human cells in vitro and in mice in vivo | |
US20040110243A1 (en) | High-throughput assay of hematopoietic stem and progenitor cell proliferation | |
Atlante et al. | Detection of reactive oxygen species in primary cultures of cerebellar granule cells | |
Gerdes et al. | Nuclear size and DNA content in rat cardiac myocytes during growth, maturation and aging | |
VAN WAARDE et al. | Acidosis (measured by nuclear magnetic resonance) and ethanol production in anoxic goldfish acclimated to 5 and 20 C | |
Cutaia et al. | Effect of hyperoxia and exogenous oxidant stress on pulmonary artery endothelial cell Na+/H+ antiport activity | |
Rickard et al. | The bone marrow colony forming cell in megaloblastic anaemia and iron deficiency anaemia | |
Rabinovitch et al. | Measurements of cell physiology: Ionized calcium, pH and glutathione |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
NENP | Non-entry into the national phase in: |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06710557 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06710557 Country of ref document: EP Kind code of ref document: A2 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 6710557 Country of ref document: EP |